Edwards Lifesciences (EW) Net Income towards Common Stockholders (2009 - 2025)

Edwards Lifesciences' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $27.0 million for Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 31.3% year-over-year to $27.0 million in Q4 2025; TTM through Mar 2026 was $20.6 million, a 99.25% decrease from a year earlier, with the FY2025 full-year figure at $13.4 million, down 99.52% from the prior year.
• Net Income towards Common Stockholders advanced to $27.0 million in Q4 2025 per EW's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $2.7 billion in Q3 2024 and bottomed at -$7.2 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is $194.7 million (2021), against an average of $314.6 million.
• Across the five-year window, Net Income towards Common Stockholders soared 5447.75% in 2024 and sank 540.0% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $335.3 million in 2021, then advanced by 18.82% to $398.4 million in 2022, then sank by 90.81% to $36.6 million in 2023, then rose by 7.38% to $39.3 million in 2024, then slumped by 31.3% to $27.0 million in 2025.
• Per Business Quant, the three latest EW Net Income towards Common Stockholders figures stand at $27.0 million (Q4 2025), -$2.0 million (Q3 2025), and -$4.4 million (Q2 2025).